ArticleJournal of medical case reports2025
Cefazolin-induced coagulopathy: a case report.
Article in Journal of medical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveWe report a case of cefazolin-induced coagulopathy, highlighting the importance of maintaining a high index of suspicion for this rare adverse effect of cefazolin.
settingDepartment of intensive care, Rabin Medical Center, Hasharon Hospital, Petach Tikvah, Israel. PATIENT: A patient presented with shortness of breath, pleural effusion, iatrogenic pneumothorax, and bacteremia (positive for coagulase-negative staphylococcus).
interventionsMultiple thoracic drains and high-dose cefazolin therapy (2 gr intravenously three times per day). CASE REPORT: A 78-year-old Caucasian woman with a history of mild renal dysfunction, chronic obstructive pulmonary disease, and morbid obesity was admitted to the Emergency Medicine Ward with new-onset shortness of breath. Initial evaluation revealed pleural effusion and positive blood cultures for Staphylococcus lugdunensis. Consequently, high-dose intravenous cefazolin (2 gr three times per day) was initiated. The patient's clinical condition deteriorated, necessitating mechanical ventilation and continuous renal replacement therapy in the intensive care unit. Management included echocardiography, placement of three pleural drains to address pneumothoraces, and intravenous antibiotic therapy. On the fourth day of cefazolin treatment, the patient experienced a significant rise in international normalized ratio (inr = 20 at day 4) levels, reaching 15-20, despite the absence of overt bleeding. After ruling-out primary hematologic disorders, cefazolin-induced coagulopathy was suspected. Cefazolin was discontinued, and vitamin K supplementation was promptly administered. This intervention led to a rapid normalization of international normalized ratio levels.
conclusionCefazolin-induced coagulopathy is a potentially life-threatening complication that may present with or without overt bleeding a few days after initiating intravenous cefazolin therapy. Owing to its rarity, this adverse effect requires heightened awareness and familiarity with predisposing risk factors to ensure timely recognition and management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.